William Kirsh, DO, MPH, Chief Medical Officer of Sentry Data Systems, has published an article in Pharmaceutical Executive magazine. The article, “A Broken System – Making Drug Decisions without Real-World Data,” discusses how using real-world data and real-world evidence to make formulary drug decisions can benefit both patients and health systems.
Sally Cornet, MBA, SPHR, GPHR and Vice President of Human Resources at Sentry Data Systems, was recently recognized as an outstanding HR professional by South Florida Business & Wealth.
Sentry recently announced the award of a patent related to its Care Improvement and Cost Reduction Analytics Methodology. The patented technology promises to radically change the trajectory of healthcare.
Sentry cleared an important hurdle in its litigation against CVS Pharmacy Inc. (“CVS”) on Wednesday when a federal court denied in its entirety CVS’s motion to dismiss Sentry’s lawsuit against CVS.
Lisa Scholz, PharmD, Head of Industry Relations at Sentry, has been named among the “Top 25 Women in Pharmacy” by Dr. Hillary Blackburn, creator of the Talk to Your Pharmacist podcast series from the Pharmacy Advisory Group.
John Ceraolo, Sentry’s Chief Information Security Officer, will be presenting at the upcoming InfoSec World 2019 Conference and Expo, April 1-3, at Disney's Contemporary Resort, Lake Buena Vista, FL.
Sentry Data Systems, Inc, a leader in tech-enabled services that support advanced healthcare analytics and 340B compliance solutions, has announced that Maury Regional Health has named Doreen Foster, Sentry’s Regional VP of Sales, as Maury’s Business Partner of the Year for 2018.
The article, "Data as Currency: The Value of Longitudinal Data for Pharma," discusses how pharmaceutical companies can use longitudinal data to their advantage, including for more accurate representation of medication effects, to reduce costs and narrow the focus of R&D efforts, and for improved post-market monitoring.
In a big win for the 340B community, FierceHealthcare has reported that Caremark will not be putting in place the planned reimbursement changes to 340B pharmacies that it had announced late last year.